News
-
Aclarion Publishes 2026 Shareholder Letter from the Chairman
February 5, 2026 -
2026 Annual Shareholder Letter from the Chairman
February 5, 2026 -
Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
February 3, 2026 -
Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
January 13, 2026 -
Aclarion Provides 2025 Update and 2026 Corporate Outlook
January 8, 2026 -
Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data
January 6, 2026 -
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
December 4, 2025 -
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
December 2, 2025 -
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
November 5, 2025 -
Aclarion Wins "Rising Star" at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
October 22, 2025